New Prognostic Insights for Surgery in Locally Advanced Pancreatic Cancer

Surgeons should note that preoperative treatment duration over six months significantly improves survival outcomes for patients undergoing conversion surgery for unresectable locally advanced pancreatic cancer.

• Patients receiving >6 months of preoperative treatment showed median overall survival of 50.4 months versus 29.7 months for those with ≤6 months (p<0.001).
• Identifying four key prognostic factors can stratify risk: long treatment duration, FOLFIRINOX regimen, normal tumor markers, and high nutritional index.

These findings could enhance patient selection and treatment planning in surgical settings.

• Patients with three or more favorable factors had a 5-year survival rate of 59.8%, compared to 26.3% for those with fewer.